Skip to content
Parakho

SMS Pharmaceuticals Ltd

NSE SMSPHARMABSE 532815smspharma.com

Q1 FY27, unaudited

Revenue
₹206.96 Cr
Profit after tax
₹20.91 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations206.96+5.57%886.87
Other income1.74+194.12%8.35
Total income208.71+6.14%895.22
Employee benefit expense23.54+29.45%87.96
Finance costs5.50−5.84%23.08
Depreciation & amortisation9.99+2.44%39.92
Total expenses181.50+5.36%778.59
Profit before tax27.21+11.64%116.64
Tax expense7.00+23.87%28.64
Profit after tax20.91+2.04%101.99
Total comprehensive income20.84+2.16%102.09
Earnings per share
Earnings per share, basic₹2.23₹11.15
Earnings per share, diluted₹2.23₹11.15

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Q4 FY26

SMS Pharmaceuticals reported 13% revenue growth to INR887 crores and EBITDA margin expansion to 20% for FY26, with PAT rising 47% to INR102 crores including a contribution from associate VKT Pharma. Management attributed the improvement to backward integration in ibuprofen, favorable product mix and operating leverage, while noting the anti-diabetic segment was deprioritized in favor of ARV and anti-inflammatory APIs. For FY27, management guided to 15% revenue growth and further margin improvement from the FY26 level of 20%, citing geopolitical uncertainty affecting logistics and raw material costs.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.

Read the full summary

Filings

12 shown · 52 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 07 Oct 2026.